|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Sherman Biotech Inc. Plans Studies And Clinical Trials For Treatment Of Anxiety Associated With Fragile X Syndrome, Autism
10/17/2006 10:57:41 AM
CHICAGO--(BUSINESS WIRE)--Sherman Biotech Inc., a wholly-owned subsidiary of Early Detect, Inc., announced today that it has scheduled seminars this fall in Chicago, Boston and New York City to discuss the company’s plans to begin preclinical studies and clinical trials of SB15, a newly-formulated compound for the treatment of anxiety associated with fragile X syndrome and autism. SB15 shows promise as an alternative to current drug therapies, such as stimulants, antidepressants and anticonvulsants that broadly suppress anxiety in individuals with these conditions. “Our research shows that the formulated version of SB15 could have therapeutic benefits for anxiety in appropriate patients,” said Dr. David Schwartz, Sherman Biotech’s chief science officer.
|
|
|
|
|
|
|
|
|
|
|